| Literature DB >> 31170381 |
Madanraj Appiya Santharam1, Farhan Ullah Khan2, Muhammad Naveed3, Usman Ali4, Muhammad Zaeem Ahsan4, Puregmaa Khongorzul5, Rana Muhammad Shoaib4, Awais Ullah Ihsan6.
Abstract
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a frustrating syndrome. The pathogenesis and state of the art treatment of CP/CPPS are not known. A wide variety of therapies including anti-inflammatories, antibiotics, alpha-blockers, neuropathic pain modulators, and 5α-reductase inhibitors are in practice. These treatment strategies focus on alleviating symptoms in specific domains without treating root-cause and therapeutic outcome is far from satisfactory. We review the literature on current pharmacological treatments for CP/CPPS in detail and suggest future perspectives to modify the treatment strategies. We suggest that introducing novel treatment strategies such as gene editing, and Tregs expressing chimeric receptors may improve the treatment outcomes by inducing immune tolerance and controlling expression of pro-inflammatory cytokines.Entities:
Keywords: Chronic prostatitis/Chronic pelvic pain syndrome; Diagnosis; Etiology; Future CP/CPPS therapies; Treatment
Year: 2019 PMID: 31170381 DOI: 10.1016/j.ejphar.2019.172429
Source DB: PubMed Journal: Eur J Pharmacol ISSN: 0014-2999 Impact factor: 4.432